ArcBest (ARCB) Tops Q2 EPS by 6c

ArcBest (NASDAQ: ARCB) reported Q2 EPS of $4.00, $0.06 better than the analyst estimate of $3.94. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.39 billion.

For earnings history and earnings-related data on ArcBest (ARCB) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c